Q-omics provides the consensus-scored KDSR profile across patient tissues and cancer cell-line models. KDSR expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, KDSR is differentially expressed in 12, with the highest sampling consensus in KIRC. Additionally, KDSR RNA expression shows 20,655 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KIRC, and ACC as cancer lineages where KDSR shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for KDSR — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes KDSR survival associations across molecular data types. KDSR RNA expression shows survival associations in the most cancer types (22), followed by mutation status (2) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible KDSR RNA expression–survival associations across cancer types. High KDSR expression shows unfavorable associations in BLCA, STAD, ACC and PAAD, but favorable associations in KIRC and BRCA. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for KDSR RNA expression.
This table summarizes KDSR tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 5. The strongest signals are observed in KIRC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for KDSR. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. KDSR shows lower tumor expression in THCA, UCEC, LUAD and BRCA and higher tumor expression in KIRC and HNSC. The KIRC box plot shows higher KDSR RNA expression in tumor versus normal tissue (log2 FC = +0.519, t-test p < 0.001).
This table shows molecular features associated with KDSR in patient tissues and cancer cell lines. In patient samples, KDSR shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, KDSR RNA and mutation anchors are most strongly linked to RNA-expression features, especially in STOMACH, while CRISPR and shRNA rows add functional-dependency signals in LUNG_SCLC and LARGE_INTESTINE.
